This Growth Stock Has Market-Beating Potential
So here's the bad news: Novavax (NASDAQ: NVAX) isn't beating the market today. Shares of the biotech company have lost a whopping 56% this year -- while the S&P 500 has slipped about 6%. That's after Novavax soared more than 3,400% over the past two years. Why such a change? Investors lost faith in the company as it fell behind in its regulatory submissions for its coronavirus vaccine candidate. Since, Novavax has gotten back on track. But the shares clearly haven't followed.
Now, here's the good news: Novavax still has market-beating potential over the long term -- even if it missed out on selling vaccine doses during the earlier stages of the pandemic. Why do I say this? Let's take a closer look at this biotech company and find out.
Image source: Getty Images.
Source Fool.com
